Chemomab Therapeutics Ltd.
CMMB · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | — | -57.77K | -28.53M | -27.65M | -9.68 |
| 2023 FY | — | -66.83K | -25.46M | -24.22M | -8.22 |
| 2024 FY | — | -53.25K | -14.74M | -13.95M | -3.12 |
| 2025 FY | — | — | -9.57M | -9.00M | -1.42 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 43.06M | 6.84M | 13.52M | 214.00K | 36.22M |
| 2023 FY | 22.15M | 5.15M | 9.29M | 392.00K | 17.00M |
| 2024 FY | 16.96M | 3.43M | 6.07M | 324.00K | 13.54M |
| 2025 FY | 13.81M | 1.48M | 7.56M | — | 12.33M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -20.29M | -67.73K | -20.36M | — | -47.57M |
| 2023 FY | -23.55M | -2.99K | -23.55M | — | -4.23M |
| 2024 FY | -15.46M | 4.96 | -15.46M | — | -3.22M |
| 2025 FY | -11.22M | -3.03K | -11.22M | — | 1.42M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 36.41M | 23.11M | — | — | — |
| 2023 FY | 5.99M | -2.91M | — | — | — |
| 2024 FY | 32.49M | 26.75M | — | — | — |
| 2025 FY | 10.52M | 2.96M | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | — | — | -2.26M | -2.06M | -0.36 |
| 2025 Q3 | — | — | -1.84M | -1.74M | -0.28 |
| 2025 Q4 | — | — | -1.99M | -1.88M | -0.24 |
| 2026 Q1 | — | — | -1.85M | -1.77M | -0.22 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 11.13M | 1.43M | 5.45M | — | 9.70M |
| 2025 Q3 | 12.37M | 1.14M | 6.97M | — | 11.23M |
| 2025 Q4 | 13.81M | 1.48M | 7.56M | — | 12.33M |
| 2026 Q1 | 11.81M | 1.11M | 5.91M | — | 10.70M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | — | — | — | — | -2.88M |
| 2025 Q3 | — | — | — | — | 1.53M |
| 2025 Q4 | -11.22M | -3.03K | -11.22M | — | 440.87K |
| 2026 Q1 | — | — | — | — | — |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 26.88M | 21.44M | — | — | — |
| 2025 Q3 | 16.25M | 9.28M | — | — | — |
| 2025 Q4 | 12.90M | 5.34M | — | — | — |
| 2026 Q1 | 12.53M | 6.62M | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |